In development: Guidance, quality standards and advice

Skip to filters Skip to results

Showing 51 to 60 of 375

Sort by

Type: Guidance`Remove $Type: Guidance filter`

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Brentuximab vedotin with etoposide, cyclophosphamide, doxorubicin, dacarbazine and dexamethasone for untreated advanced classical Hodgkin lymphoma [ID6437]	Technology appraisal guidance	6 May 2027
Brexucabtagene autoleucel for treating relapsed or refractory mantle cell lymphoma after 2 or more systemic treatments (review of TA677) [ID6325]	Technology appraisal guidance	11 February 2026
Cabozantinib for treating advanced hepatocellular carcinoma after prior therapy [ID1243]	Technology appraisal guidance	24 May 2019
Cabozantinib for treating advanced neuroendocrine tumours that have progressed after systemic treatment [ID6474]	Technology appraisal guidance	TBC
Canagliflozin for treating chronic kidney disease in people with type 2 diabetes [ID1653]	Technology appraisal guidance	TBC
Capsule sponge tests for detection of Barrett's oesophagus and early-stage oesophageal cancer and surveillance of Barrett's oesophagus [ID6683]	Technology appraisal guidance	24 February 2027
Cardiometabolic disease prevention and treatment guidelines	NICE guideline	TBC
CaRi-Heart for predicting cardiac risk in adults with suspected coronary artery disease (CAD)	Health technology evaluation	2 December 2026
Catumaxomab for intraperitoneal treatment of malignant ascites in epithelial cellular adhesion molecule-positive carcinomas when further systemic anticancer treatment is unsuitable [ID6580]	Technology appraisal guidance	30 September 2026
Cediranib with olaparib for treating recurrent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer after 3 therapies [ID1639]	Technology appraisal guidance	TBC

Results per page

10
25
50
All